Table 3.
Market shares of conventional recombinant products for paediatric and adult patients
| Paediatrics | Adults | |
|---|---|---|
| Advate® | 30% | 24% |
| Kogenate® | 29% | 23% |
| Refacto® | 23% | 18% |
| Helixate® | 17% | 13% |
| Recombinate® | 1% | 1% |
| Plasma-derived products | – | 21% |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.